Skip to main content

Drug Interactions between gemfibrozil and vadadustat

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

gemfibrozil vadadustat

Applies to: gemfibrozil and vadadustat

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with moderate or potent inhibitors of the uptake transporters organic anion transporter 1 and/or 3 (OAT1, OAT3) may increase the plasma concentrations and the risk of adverse effects associated with vadadustat. According to the manufacturer, coadministration with probenecid, a potent OAT1/OAT3 inhibitor, increased systemic exposure (AUC) of vadadustat by almost 2-fold. Increased systemic exposure to vadadustat may result in a rapid rise in hemoglobin and increase the risk of adverse reactions such as thromboembolic events, diarrhea, hypertension, liver injury, seizures, pneumonia, and increased cardiovascular and mortality risk.

MANAGEMENT: Close clinical and laboratory monitoring for adverse effects is advised if vadadustat is used concomitantly with moderate or potent OAT1 and/or OAT3 inhibitors. Additionally, close monitoring of hemoglobin levels is advised following initiation or discontinuation of treatment with moderate or potent OAT1/OAT3 inhibitors, and the vadadustat dosage adjusted as necessary in accordance with the prescribing information.

Drug and food interactions

Moderate

vadadustat food

Applies to: vadadustat

Consumer information for this interaction is not currently available.

MONITOR: Smoking and alcohol consumption during therapy with vadadustat may increase the risk of gastrointestinal erosions. Serious erosions, including gastrointestinal bleeding and the need for red blood cell transfusions, have been reported during vadadustat clinical trials. Patients with a history of gastrointestinal erosion, peptic ulcer disease, and current tobacco smokers and alcohol drinkers may be at higher risk of gastrointestinal injury.

MANAGEMENT: Caution is advised if vadadustat is prescribed to current tobacco smokers or alcohol drinkers. Patients should be advised to contact their physician if they develop potential signs and symptoms of gastrointestinal injury such as abdominal pain, hematemesis, trouble swallowing, chest or throat pain, and/or black, tarry stools.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer